Results 81 to 90 of about 4,770 (180)
Respirology Case Reports, Volume 14, Issue 3, March 2026.Cystic fibrosis (CF) modulator therapies can lead to rapid and excessive weight gain. Obesity in CF can lead to undesirable metabolic complications including type 2 diabetes. Therefore, glucagon‐like peptide 1 (GLP‐1) agonists which can facilitate weight loss and improve metabolic profiles are increasingly prescribed to people with CF.
Shanal Kumar +4 more
wiley +1 more source
Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations:A Systematic Review [PDF]
BACKGROUND AND OBJECTIVE: Following the development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators (ivacaftor, tezacaftor, elexacaftor, and lumacaftor), the prognosis for people diagnosed with cystic fibrosis (pwCF) has improved.
Akkerman, Onno W +7 more
core +1 more source
BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 4, Page 690-697, March 2026.ABSTRACT Objective A comprehensive review of maternal, obstetric and neonatal outcomes in pregnancies in females with cystic fibrosis (fwCF) following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy in a novel, dedicated CF‐Maternal Health service.
Rebecca Scott +12 more
wiley +1 more source
Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor–tezacaftor–ivacaftor combination: a 1-year observational study [PDF]
Background: To limit the progression of disease, people with cystic fibrosis (pwCF) perform daily respiratory physiotherapy, which is perceived as the most burdensome routine in managing their condition.
Blardone, Chiara +12 more
core +1 more source
ERJ Open ResearchBackground People living with cystic fibrosis in Denmark had early, universal access to triple modulator treatment with elexacaftor/tezacaftor/ivacaftor.
Christian Leo-Hansen +19 more
doaj +1 more source
Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry [PDF]
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has improved outcomes for people with cystic fibrosis (pwCF). This study evaluated changes in airway microbiological infection status after initiating ETI.
De Rose, Virginia +7 more
core +1 more source
Management of Cystic Fibrosis‐Related Diabetes in Denmark—A Population‐Based, Cross‐Sectional Study
Pediatric Pulmonology, Volume 61, Issue 2, February 2026.ABSTRACT Background Cystic fibrosis‐related diabetes (CFRD) is the most common comorbidity in cystic fibrosis (CF). After the introduction of modulator therapy, extended life expectancy and altered nutritional status may have changed the landscape of CFRD. This study aimed to evaluate the current CFRD management in Denmark.
Ingrid Grimsgaard +6 more
wiley +1 more source
Anales de PediatríaResumen: Introducción: Los tratamientos con moduladores de la proteína CFTR han mejorado la salud respiratoria y digestiva de los pacientes con fibrosis quística.
Ruth García Romero +14 more
doaj +1 more source
Effects of cAMP and CFTR modulation on apical fluid pH in human airway Calu‐3 cells
Physiological Reports, Volume 14, Issue 3, February 2026.Abstract The airway epithelium serves as the first line of defense against inhaled insults present in the external environment by acting as a physical barrier and through host defense mechanisms. Proper maintenance of these host defense mechanisms relies on the regulation of airway surface liquid (ASL) composition and properties, a process that is ...
Jenny P. Nguyen +2 more
wiley +1 more source
Anales de Pediatría (English Edition)Introduction: Treatments with CFTR protein modulators have improved respiratory and digestive health in patients with cystic fibrosis. Objective: To assess changes in intestinal inflammation through the analysis of fecal calprotectin in patients with ...
Ruth García Romero +20 more
doaj +1 more source